#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marginal zone lymphoma Thalassaemia beta Cutaneous T-cell lymphoma stage II Obesity Fatty acid oxidation disorder Congenital pseudarthrosis Antithrombin III deficiency Hepatitis B Nephropathy Monogenic diabetes Hypoxic-ischaemic encephalopathy Cutaneous T-cell lymphoma stage I Peritoneal neoplasm Rosai-Dorfman syndrome Nephroblastoma More trials…

    Learn about Rare Diseases

    Testicular leiomyosarcoma – Trials in Disease Mantle cell lymphoma stage II Alport’s syndrome – Diagnostics Paroxysmal nocturnal haemoglobinuria – Life with Disease Marginal zone lymphoma refractory – Life with Disease Hepatoblastoma – Basic Information Mantle cell lymphoma – Trials in Disease Cystic fibrosis – Basic Information Pemphigoid – Trials in Disease Indolent systemic mastocytosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Valsartan Elotuzumab Clonidine Hydrochloride Mitazalimab Db-1303 Charcoal, Activated Calcium Pantothenate Bp Olodaterol Insulin Aspart Enmetazobactam AP31969 SULFATE Piperacillin Vildagliptin Eletriptan MARALIXIBAT OMTX705 Aminocaproic Acid GS-1720 Enfuvirtide Eculizumab More therapies…

    Learn about Your Condition

    Rosai-Dorfman syndrome Pancreaticoduodenectomy Chondroplasty Anal abscess Macular degeneration Myxofibrosarcoma Craniocerebral injury Alveolar bone defect Chronic hepatitis C Ejection fraction normal Ovarian granulosa cell tumour Epstein-Barr virus infection Breast cancer stage III Arterial tortuosity syndrome Leber's congenital amaurosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Sanitaria Universitaria Giuliano Isontina

Azienda Sanitaria Universitaria Giuliano Isontina

Strada Di Fiume 447, Trieste, 34149, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Single Guide Rna Targeting The Human Ttr Gene
    • Ziclumeran
    • Famotidine
    Austria Belgium Czechia Denmark France Germany +8

  • Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Aficamten
    Czechia Denmark France Germany Greece Hungary +6

  • Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Lenalidomide
    • Teclistamab
    Austria Belgium Czechia Denmark France Germany +7

  • Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Bendamustine
    • Ibrutinib
    • Rituximab
    Germany Italy

  • Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic kidney disease
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Bulgaria Czechia Denmark Finland France Germany +8

  • Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

    Recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • ZIGAKIBART
    Belgium Croatia Czechia France Germany Greece +2

  • A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiac amyloidosis
    Belgium Czechia Denmark France Germany Italy +2

  • Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Belgium France Germany Italy Portugal

  • A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Heart failure with reduced ejection fraction
    Bulgaria Czechia Germany Hungary Italy The Netherlands +4

  • Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

    Not yet recruiting

    2 1
    Bulgaria Czechia Germany Italy Poland
Previous Page
1 … 3 4 5 6 7 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!